<DOC>
	<DOCNO>NCT01846104</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity single 50-μg booster dose RVEc . Subjects recruit cohort receive three 50-μg dos RVEc Phase 1 trial ( NCT01317667 ) .</brief_summary>
	<brief_title>Booster Dose ( 50 µg ) Recombinant Ricin Toxin Vaccine ( RVEc™ ) Previously Vaccinated Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Poisoning</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Study subject must receive 3 prim dos RVEc 50µg dosage . Study subject must 18 year old time screen old 50 year old time vaccination . Subjects must weigh least 110 pound time screen . Subjects must good health judge medical history , physical examination , EKG , hematology , clinical chemistry , urinalysis , hepatitis serology , HIV antibody test ( Table 4 ) medically clear participation investigator . If HIV hepatitis test positive , individual provide counsel referral health care . Females childbearing potential must negative pregnancy test screen morning vaccination prior receipt vaccine must agree use highly effective method birth control first 3 month follow receipt RVEc . A highly effective method birth control define one failure rate le 1 % per year . Acceptable birth control method meet criterion include hormonal implant injectables ( Norplant , DepoProvera , Lunelle , Etonogestrel ) , combine oral contraceptive , intrauterine device ( IUDs ) Copper T ( 380A ) Mirena ( Levonorgestrel Intrauterine System ) , female sterilization ( tubal ligation ) , sexual abstinence , vasectomized partner . Female subject must also agree breastfeed least 3 month receive RVEc . Study subject must read sign approve informed consent . Study subject must willing return followup visit . Study subject must agree report AE may may associate administration investigational product 6month followup/closeout visit . Study subject must agree abstain excessive exercise ( usual routine ) excessive alcohol consumption ( exceed 2 drink male 1 drink female daily binge drink ) duration study participation . Acute chronic medical condition immunodeficiency medical condition medical treatment , medication , dietary supplement , investigator 's opinion , would impair subject 's ability respond vaccination . Use corticosteroid , inhaled corticosteroid , permit . Severe hypersensitivity vaccine ( anaphylaxis , angioedema , bronchospasm , laryngospasm ) . History asthma , chronic obstructive pulmonary disease , current/residual disease lung . Clinically significant abnormal laboratory test . Current smoker . Any known allergy sodium succinate , Tween20 ( detergent ) , aluminum hydroxide , kanamycin . Receipt vaccine investigational product within 30 day vaccination RVEc . Receipt RVEc contraindicate base SIRVA checklist/screening , determine PI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>